Think Tanks et al

Think Tanks et al
Brookings [to 23 Oct 2021]
Discrimination in the healthcare system is leading to vaccination hesitancy
Gabriel R. Sanchez, Matt Barreto, Ray Block, Henry Fernandez, and Raymond Foxworth
Wednesday, October 20, 2021
Center for Global Development [to 23 Oct 2021]
Accessed 23 Oct 2021
Economic and Programmatic Implications for the Covid-19 Vaccine Roll Out in Africa
Curbing the pandemic while protecting access to essential health services requires an ample supply of vaccine, a functioning, well-funded delivery system, and careful planning.

ODA Rules Must Ensure that Vaccine Donations Count for the Poor
October 21, 2021
After buying up the World’s vaccine supply to ensure they can protect their own populations, rich countries have found themselves struggling to use the vaccine surpluses they accumulated. One response has been to donate the spare doses to countries who need them more. This is laudable, and countries who have done so want to receive credit for such actions in their aid statistics—what is known as Official Development Assistance (ODA).
Euan Ritchie, Anthony McDonnell and Ranil Dissanayake

We Should Track Global Vaccine Manufacturing Better – Here Is Why, and How
October 21, 2021
Poor understanding about vaccine capacity was one of the reasons why the world did not have the infrastructure needed to manufacture sufficient doses. This blogs proposes three actions to start tracking manufacturing capacity better and create robust estimates for the world’s vaccine manufacturing capacity.
Anthony McDonnell et al.
Chatham House [to 23 Oct 2021]
Accessed 23 Oct 2021
[No new digest content identified]


Accessed 23 Oct 2021
[No new digest content identified]


Kaiser Family Foundation
[No new digest content identified]

ODI [Overseas Development Institute] [to 23 Oct 2021]
What MDBs (and their shareholders) can do for vaccine equity
06 October 2021
In late 2020 the World Bank and the Asian Development Bank (AsDB) announced large-scale financing packages to help the rollout of Covid-19 vaccines in low- and middle-income countries. But despite the urgency of doing this to bring the global pandemic to an end, the uptake of these financing packages has so far been slow. Why are committed funds sitting idle at the same time that vaccination programmes are a priority in many countries battling new waves of Covid-19 infections? And at the same time as many activists and world leaders call on G7 leaders to ramp up their contributions to the global vaccination effort?

In this long-read we review some of the factors and bottlenecks that can plausibly explain this low uptake of MDB financing for vaccine purchases from governments in low-and middle-income countries. More importantly, we outline what management and shareholders of MDBs should do to ramp up the use of these financing facilities or deploy resources to support the health response against Covid-19. The fundamental issue has been between the country-based lending model of MDBs and the need to finance and procure a global public good (a low-cost vaccine). MDBs thus need a clearer mandate and dedicated grant financing for global public goods, including vaccine procurement.